根据名称进行药物检索

Aceon 与 Potassium Citrate and Citric Acid Powder Pack

Aceon 与 Potassium Citrate and Citric Acid Powder Pack互相作用以及同时服用的可能性。

检测结果:

Aceon <> Potassium Citrate and Citric Acid Powder Pack

现实性: 08.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前使用普利一起柠檬酸钾。结合这些药物可能会大大增加钾水平的血液。高水平的钾可以发展成为一个称为高血钾，这在严重的情况下可能导致肾衰竭、肌肉麻痹、非正规心脏的节奏，和心脏骤停。你可以更容易患高血钾同时使用这些药物的，如果你是老年人、脱水，或有肾脏病、糖尿病或高级心脏衰竭。定期或长期使用的非甾体抗炎药物，如布洛芬或生(止痛药)也可能增加你的风险。重要的是你保持足够的流体摄入量在处理与这些药物。此外，谈谈你的医生来看看你是否应该限制钾消耗量丰富的食品，如西红柿、葡萄干图、马铃薯、青豆、香蕉、大蕉、番木瓜、梨、甜瓜、芒果、钾含盐的替代品。你可能需要的剂量调整或更频繁的监测通过你的医生到安全地使用这两种药物。你应该寻求医疗照顾，如果你遇到恶心、呕吐、无力、混乱、麻刺的手和脚，感觉头重脚轻的腿,一个脉搏微弱，或者减缓或心跳不规则，因为可以将这些症状的高血钾. 重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

密切监测：伴随使用的血管紧张素转换酶(ACE)，抑制剂和钾盐可能会增加风险的高血钾. 抑制ACE结果在下降醛固酮分泌，这又导致钾的保留。在一个报告，有明显增加血钾水平(3.88 +/- 0.41 要4.84 +/- 0.45 mEq/L)观察到在一天或两天后除了卡托普利在五个病人治疗方案，包括补充钾或钾利尿剂。三个病人不得不实验室诊断的高血钾，包括一个病人接受补充钾谁了66%提高血钾。水平仍然很高，直到补充钾或巯治疗是减少或停止。在上市后调查的病人规定的那普利在英格兰之间的四月至十二月1985年，研究人员确定了十个情况下，这种药物似乎有助于降肾功能和随后死亡。所有十个患有高血钾，七人还接受中度到高剂量的钾利尿剂和/或钾的补充。高血钾被认为是死亡的直接原因，在他们两个。风险因素对发展中严重或威胁生命的高血钾可以包括肾脏受损、糖尿病、年老、严重或日益恶化的心脏衰竭、脱水，而同时使用其他药剂，阻止肾素-血管紧张素醛固酮的系统或以其他方式增加血钾的水平。

管理：谨慎建议，如果ACE抑制剂的使用必须同时与钾盐，特别是在患有肾损伤、糖尿病、年老、严重或日益恶化的心脏衰竭、脱水，或者伴随治疗与其他代理，提高血钾如非甾体抗炎药物，β受体阻滞剂，孢菌素、肝素藤,此药物，而甘草。结合通常应该避免在这些患者，除非绝对必要和好处会超过潜在的风险。血钾和肾功能应该进行检查之前启动治疗和定期后。患者应给予心理咨询在适当级别的钾和液体摄入，并建议寻求医疗注意，如果他们的经验的迹象和症状的高血钾这样的恶心、呕吐、无力、精神萎靡，刺痛的四肢瘫痪，混淆，脉搏微弱和缓慢或不规则心跳。

来源

"Product Information. K-Dur (potassium chloride)." Schering Laboratories, Kenilworth, NJ.
Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61
Large DM, Carr PH, Laing I, Davies M "Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism." Postgrad Med J 60 (1984): 370-3
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association "Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association." Circulation 104 (2001): 1985-91
Warren SE, O'Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2
Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14
Perazella MA, Mahnensmith RL "Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis." J Gen Intern Med 12 (1997): 646-56
Schuna AA, Schmidt GR, Pitterle ME "Serum potassium concentrations after initiation of captopril therapy." Clin Pharm 5 (1986): 920-3
Lawson DH, O'Connor PC, Jick H "Drug attributed alterations in potassium handling in congestive cardiac failure." Eur J Clin Pharmacol 23 (1982): 21-5
Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20
Speirs CJ, Dollery CT, Inman WH, et al "Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure." Br Med J 297 (1988): 830-2
Packer M, Lee WH "Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure." Am J Cardiol 57 (1986): 347-8
Jarman PR, Kehely AM, Mather HM "Hyperkalaemia in diabetes: prevalence and associations." Postgrad Med J 71 (1995): 551-2
Obialo CI, Ofili EO, Mirza T "Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease." Am J Cardiol 90 (2002): 663-5
Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70
Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2
Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN "Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis." Hypertension 1 (1979): 279-80
Graves JW "Hyperkalemia due to a potassium-based water softener." N Engl J Med 339 (1998): 1790-1
Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40
Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12
Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538
Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812
Stoltz ML, Andrews CE Jr "Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use ." JAMA 264 (1990): 2737-8
Reardon LC, Macpherson DS "Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?" Arch Intern Med 158 (1998): 26-32